A six-month trial of the antiepileptic drug topiramate (TOPAMAX, Ortho-McNeil Pharmaceutical, Inc) for the treatment of obesity has found the drug helped reduce body weight between 6 percent and 8 percent, the principal investigator announced.
Dr. George Bray, formerly executive director of the Pennington Biomedical Research Center, Baton Rouge, La., said weight loss continued at the six-month cut-off point. In contrast, he said, the two weight-loss drugs currently on the market, orlistat (Xenical, Roche) and sibutramine (Meridia, Abbott Laboratories) plateau between three and six months, he said.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!